Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: A systematic review and meta-analysis

Catherine A Hogan, Lekha Puri, Genevieve Gore, Madhukar Pai, Catherine A Hogan, Lekha Puri, Genevieve Gore, Madhukar Pai

Abstract

Background: Fluoroquinolones are among the most commonly used antibiotics for the treatment of respiratory infections. Because fluoroquinolones show bactericidal activity against Mycobacterium tuberculosis, there is concern that their use can delay the diagnosis of tuberculosis. We conducted a systematic review and meta-analysis to assess whether empiric treatment with fluoroquinolones delays the diagnosis and treatment of tuberculosis in patients with respiratory tract infections.

Objectives: The primary objective was to assess the delay in days in the diagnosis and treatment of tuberculosis, among patients who received quinolones, compared to those who received non-fluoroquinolone antibiotics.

Methods: We included studies of adult patients treated with fluoroquinolones prior to a confirmed diagnosis of tuberculosis. We performed a literature search of 7 databases (including PubMed, Embase and Cochrane Library) with no language restrictions. We calculated an unweighted mean of estimate of difference in delay across all studies. For the studies for which the estimate was available as a mean with standard deviation, a weighted average using a random effects meta-analysis model was estimated.

Results: A total of 3983 citations were identified from the literature search; of these, 17 articles were selected for full-text review. A total of 10 studies were retained for the synthesis. These included 7 retrospective cohort studies and 3 case-control studies. Only one of these studies was from a high TB burden country, South Africa. The most commonly used fluoroquinolones were levofloxacin, gemifloxacin and moxifloxacin. The unweighted average of difference in delay between the fluoroquinolone group and non-fluoroquinolone group was 12.9 days (95% CI 6.1-19.7). When these differences were pooled using a random effects model, the weighted estimate was 10.9 days (95% CI 4.2-17.6). When stratified by acid-fast smear status, the delay was consistently greater in the smear-negative group.

Conclusion: Although results are variable, the use of fluoroquinolones in patients with respiratory infections seems to delay the diagnosis of TB by nearly two weeks. Consistent with the International Standards for TB Care, their use should be avoided when tuberculosis is suspected.

Keywords: Diagnostic delay; Fluoroquinolones; Tuberculosis.

© 2016 The Authors.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram.

References

    1. Center for Disease Dynamics, Economics and Policy . CDDEP; Washington, D.C.: 2015. State of the world's antibiotics, 2015.
    1. Tuberculosis Coalition for Technical Assistance. International standards for tuberculosis care (ISTC). The Hague: Tuberculosis Coalition for Technical Assistance, 2006.
    1. Das J., Kwan A., Daniels B., Satyanarayana S., Subbaraman R., Bergkvist S. Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study. Lancet Infect Dis. 2015;15(November(11)):1305–1313.
    1. Satyanarayana S., Kwan A., Daniels B., Subbaraman R., McDowell A., Bergkvist S. Use of standardised patients to assess antibiotic dispensing for tuberculosis by pharmacies in urban India: a cross-sectional study. Lancet Infect Dis. 2016 Aug 24.
    1. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72. Mar 1.
    1. Woodhead M., Blasi F., Ewig S., Garau J., Huchon G., Ieven M. Joint Taskforce of the European respiratory society and European Society for clinical microbiology and infectious diseases.Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011;17(November (Suppl 6)):E1–59.
    1. Chen T.C., Lu P.L., Lin C.Y., Lin W.R., Chen Y.H. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011;15(March(3)):e211–e216.
    1. Moher D., Liberati A., Tetzlaff J., Altman D.G., The PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
    1. Qin, Z.Z. Delays in diagnosis and treatment of pulmonary tuberculosis, and patient care-seeking pathways in China: a systematic review and meta-analysis. Master's thesis. 2015.
    1. Cremades R., Rodríguez J.C., García-Pachón E., Galiana A., Ruiz-García M., López P. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother. 2011;66(October(10)):2281–2283.
    1. Rush B., Wormsbecker A., Stenstrom R., Kassen B. Moxifloxacin use and its association on the diagnosis of pulmonary tuberculosis in an inner city emergency department. J Emerg Med. 2016;50(March(3)):371–375.
    1. Wang J.Y., Lee C.H., Yu M.C., Lee M.C., Lee L.N., Wang J.T. Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study. Eur Respir J. 2015;46(August(2)):567–570.
    1. Kim S.Y., Yim J.J., Park J.S., Park S.S., Heo E.Y., Lee C.H. Clinical effects of gemifloxacin on the delay of tuberculosis treatment. J Korean Med Sci. 2013;28(March(3)):378–382.
    1. Wang M., Fitzgerald J.M., Richardson K., Marra C.A., Cook V.J., Hajek J. Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic? Int J Tuberc Lung Dis. 2011;15(August(8)):1062–1068.
    1. Jeon C.Y., Calver A.D., Victor T.C., Warren R.M., Shin S.S., Murray M.B. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int J Tuberc Lung Dis. 2011;15(January(1)):77–83.
    1. Wang J.Y., Hsueh P.R., Jan I.S., Lee L.N., Liaw Y.S., Yang P.C. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax. 2006;61(October(10)):903–908.
    1. Sierros V., Khan R., Joo Lee H., Sabayev V. The effect of fluoroquinolones on the acid-fast bacillus smear and culture of patients with pulmonary tuberculosis. Clin Pulm Med. 2006;13(May(3)):164–168.
    1. Golub J.E., Bur S., Cronin W.A., Gange S., Sterling T.R., Oden B. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis. 2005;9(April(4)):392–397.
    1. Yoon Y.S., Lee H.J., Yoon H.I., Yoo C.G., Kim Y.W., Han S.K. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis. 2005;9(November(11)):1215–1219.
    1. Dooley K.E., Golub J., Goes F.S., Merz W.G., Sterling T.R. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002;34(12):1607–1612. Jun 15.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅